FOX NEWS: Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results


Antibody drug cuts moderate Alzheimer’s decline, Swiss biotech cautions over results



A Phase 2 trial involving an investigational monoclonal antibody drug, semorinemab, targeting the tau protein, reduced cognitive decline among adults with mild-to-moderate Alzheimer’s disease by about 44%, Swiss biotech AC Immune announced Tuesday.

via FOX NEWS https://ift.tt/3mS57V0

Comments

Popular posts from this blog

Your Complete Guide To Maximising Supplement Absorption

A Nutritionist On 4 Things To Consider When It Comes To Vegan Supplements

How A Love Language Can Help You Decide On The Perfect Gift